Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Brain Neoplasms 1

Interventions

pembrolizumab 9Pemetrexed 7Cyclophosphamide 6Nivolumab 5Ipilimumab 5Cisplatin 5Carboplatin 5fludarabine 4Drug Therapy 2Bevacizumab 2tremelimumab 1tocilizumab 1tazemetostat 1spartalizumab 1sotorasib 1rebastinib 1poly ICLC 1pevonedistat 1osimertinib 1milademetan 1fludarabine phosphate 1epacadostat 1durvalumab 1defactinib 1atezolizumab 1aldesleukin 1Vorinostat 1Thiostrepton 1Tablets 1Plicamycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Mesothelioma × Automobiles × Clear all
NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
15 enrolled 14 charts
GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡